Chronix Biomedical: First Patient in the World Shows Utility of Brand New Cancer Test

LONDON--()--A huge breakthrough in increasing the accuracy of cancer screening tests has been made. The method currently used has extremely poor accuracy. The new test developed by British, German and American scientists has a 91% accuracy, is expected to become the new norm and save many more lives as a result.

The new test measures DNA in the blood as opposed to the current measurement of a specific blood protein.

The first test in the world was successfully performed on a patient at a hospital in London.

The new test is now being made available to health services worldwide. It has taken 15 years of research to develop, pioneered by Chronix Biomedical.

Dr Nick Plowman, a Senior Clinical Oncologist at St. Bartholomew’s Hospital, Senior Lecturer at Queen Mary University of London and considered to be one of the UK’s leading experts in oncology is presenting the case at the William Harvey annual research day at St. Bartholomew’s Hospital.

Dr Nick Plowman commented:

“The patient in today’s case report declined having a biopsy which limited our ability to fully comprehend his medical condition. Adding a genetic blood test (cell free cancer DNA circulating in the blood) clinched the diagnosis allowing us to make a treatment decision that resulted in a positive response. These liquid biopsies will become important in the fight against cancer. ”

Dr Howard Urnovitz CEO of Chronix Biomedical added:

“Doctors need every tool at their disposal to make medically important decisions. Today’s report illustrates the clinical utility of adding the Chronix Biomedical blood test to the current test menu to assist oncologists in important treatment decisions. “

Contacts

Chronix Biomedical
ENQUIRIES
Howard Urnovitz CEO
+1 408 960 2306
or
Richard Pearson
Capital Markets Consultants
07515 587184

Contacts

Chronix Biomedical
ENQUIRIES
Howard Urnovitz CEO
+1 408 960 2306
or
Richard Pearson
Capital Markets Consultants
07515 587184